Curanex Pharmaceuticals Inc Common Stock Cash Flow-to-Debt Ratio
Curanex Pharmaceuticals Inc Common Stock cash flow-to-debt ratio. Curanex Pharmaceuticals Inc Common Stock (CURX) has a Cash Flow-to-Debt Ratio of -49.40x as of September 2025, meaning its operating cash flow of $-9.19 Million could theoretically repay -49% of its total liabilities ($185.96K) in one year. See CURX free cash flow debt coverage to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Curanex Pharmaceuticals Inc Common Stock (2023–2024)
Cash flow-to-debt ratio of Curanex Pharmaceuticals Inc Common Stock from 2023 to 2024. Historical debt coverage capacity for Curanex Pharmaceuticals Inc Common Stock across 2 annual periods. Check CURX cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Curanex Pharmaceuticals Inc Common Stock Cash Flow-to-Debt Ratio by Year (2023–2024)
Curanex Pharmaceuticals Inc Common Stock cash flow-to-debt ratio by year from 2023 to 2024. Year-by-year debt coverage analysis for Curanex Pharmaceuticals Inc Common Stock. For the full cash flow conversion analysis, see Curanex Pharmaceuticals Inc Common Stock (CURX) cash conversion ratio.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -38.12x | $-555.58K | $14.57K | ▼ -453381.3% |
| 2023 | -0.01x | $-120.00 | $14.28K | — |